Botulinum Toxin-A For Management of Migraine: An Experience in Iraq
Keywords:
Orofacial pain, Migraine, Botulinum toxinA, Chronic migraine.Abstract
Iraq as a country, doesn’t have any facts or details about using botulinum toxin for the prevention of migraine. The main goal of this experience, is to study the clinical profile and response to treatment with botulinum toxin injection for migraine patients. Migraine is a headache illness identified by repeated attacks of moderate to severe pain, nausea, photophobia, and phonophobia. Botulinumtoxin A is used to prevent and treat migraine. To estimate the effectiveness of botulinum toxin-A injections for managing migraine and prove the usefulness and safety of botulinum toxin -A. The study sample included 23 patients aged 20-45, 8 males and 15 females, diagnosed with migraines for more than one year. Patients with neurological or cardiovascular disorders and pregnant women were not included from the study. Botox powder 150 units and a 30-gauge needle were used to inject 30 injections, with 5 units of botulinum toxin in each injection site.
Downloads
References
Okeson, J. P., & Bell, W. E. (2005). Bell's orofacial pains: the clinical
management of orofacial pain. Quintessence.
Okeson, J. P. (2008). The classification of orofacial pains. Oral and
maxillofacial surgery clinics of North America, 20(2), 133-144
Sutherland, H. G., Albury, C. L., & Griffiths, L. R. (2019). Advances in
genetics of migraine. The journal of headache and pain, 20(1), 1-20.
Kurth, T., Rist, P. M., Ridker, P. M., Kotler, G., Bubes, V., & Buring, J. E.
(2020). Association of migraine with aura and other risk factors
with incident cardiovascular disease in women. JAMA, 323(22),
-2289.
Merrill, R. L. (1997). Orofacial pain mechanisms and their clinical
application. Dental Clinics of North America, 41(2), 167-188.
Daudia, A. T., & Jones, N. S. (2002). Facial migraine in a rhinological
setting. Clinical Otolaryngology & Allied Sciences, 27(6), 521-525.
Nattagh-Eshtivani, E., Sani, M. A., Dahri, M., Ghalichi, F., Ghavami, A.,
Arjang, P., & Tarighat-Esfanjani, A. (2018). The role of nutrients in
the pathogenesis and treatment of migraine headaches.
Biomedicine & Pharmacotherapy, 102, 317-325.
Natoli, J., Manack, A., Dean, B., Butler, Q., Turkel, C., Stovner, L. et al.
(2010) Global prevalence of chronic migraine: a systematic review.
Cephalalgia 30: 599- 609.
Queiroz, L., Barea, L. and Blank, N. (2006) An epidemiological study of
headache in Florianopolis, Brazil. Cephalalgia 26: 122-127.
Rasmussen, B., Jensen, R., Schroll, M. and Olesen, J. (1991)
Epidemiology of headache in a general population-a prevalence
study. J Clin Epidemiol 44: 1147- 1157.
Buse, D., Manack, A., Fanning, K., Serrano, D., Reed, M., Turkel, C. et
al. (2012) Chronic migraine prevalence, disability, and
sociodemographic factors: results from the American Migraine
Prevalence and Prevention Study. Headache 52: 1456-1470.
Katsarava, Z., Manack, A., Yoon, M., Obermann, M., Becker, H.,
Dommes, P. et al. (2011) Chronic migraine: classification and
comparisons. Cephalalgia 31: 520-529.
Aurora, S., Winner, P., Freeman, M., Spierings, E., Heiring, J., DeGryse,
R. et al. (2011) OnabotulinumtoxinA for Treatment of Chronic
Migraine: pooled Analyses of the 56-Week PREEMPT Clinical
Program. Headache 51: 1358-1373.
Buse, D., Manack, A., Serrano, D., Turkel, C. and Lipton, R. (2010)
Sociodemographic and comorbidity profiles of chronic migraine
and episodic migraine sufferers. J Neurol Neurosur Ps 81: 428-432.
Khalil, M., Zafar, H., Quarshie, V. and Ahmed, F. (2014) Prospective
analysis of the use of OnabotulinumtoxinA (BOTOX) in the treatment of chronic migraine; real-life data in 254 patients from
Hull, UK J Headache Pain 15: 54.
Cernuda-Morollon, E., Martinez-Camblor, P., Ramon, C., Larrosa, D.,
SerranoPertierra, E. and Pascual, J. (2014) CGRP and VIP levels as
predictors of efficacy of onabotulinumtoxin type A in Chronic
Migraine. Headache 54: 987-995.
Diener, H., Solbach, K., Hoile, D. and Gaul, C. (2015) Integrated care
for chronic migraine patients: epidemiology, burden, diagnosis and
treatment options. Clin Med 15: 344-350.
Schwedt, T. (2014) Chronic migraine. Brit Med J 348: gl416.
Rostron, S. (2021). The Effects of Massage Therapy on a Patient with
Migraines and Cervical Spondylosis: a Case Report. International
Journal of Therapeutic Massage & Bodywork, 14(3), 15.
Straube, A., Gaul, C., Forderreuther, S., Kropp, P., Marziniak, M., Evers,
S. et al. (2012) Therapy and care of patients with chronic migraine:
expert recommendations of the German Migraine and Headache
Society/German Society for Neurology as well as the Austrian
Headache Society/Swiss Headache Society. Nervenarzt 83: 1600-
Simpson, D. M., Hallett, M., Ashman, E. J., Cornelia, C. L., Green, M.
W., Gronseth, G. S., ... & Yablon, S. A. (2016). Practice guideline
update summary: Botulinum neurotoxin for the treatment of
blepharospasm, cervical dystonia, adult spasticity, and headache:
Report of the Guideline Development Subcommittee of the
American Academy of Neurology. Neurology, 86(19), 1818-1826.
Frank, F., Ulmer, H., Sidoroff, V., & Broessner, G. (2021). CGRPantibodies, topiramate and botulinum toxin type A in episodic and
chronic migraine: a systematic review and meta-analysis.
Cephalalgia, 41(11-12), 1222-1239.
Shaterian, N., Shaterian, N., Ghanaatpisheh, A., Abbasi, F., Daniali, S.,
Jahromi, M. J., ... & Abdoli, A. (2022). Botox
(OnabotulinumtoxinA) for Treatment of Migraine Symptoms: A
Systematic Review. Pain Research and Management, 2022..
Gupta, V. K. (2006). Botulinum toxin—a treatment for migraine? A
systematic review. Pain medicine, 7(5), 386-394.
Jabbari, B. (2016). History of botulinum toxin treatment in movement
disorders. Tremor and Other Hyperkinetic Movements, 6.
Bouloux, G. F. (2022). Botulinum toxin (Botox). Front Oral Maxillofac
Med, 4, 4.
Burstein, R., Blumenfeld, A. M., Silberstein, S. D., Manack Adams, A., &
Brin, M. F. (2020). Mechanism of action of onabotulinumtoxinA in
chronic migraine: a narrative review. Headache: The Journal of
Head and Face Pain, 60(7), 1259-1272.
Blumenfeld, A. M., Stark, R. J., Freeman, M. C., Orejudos, A., & Manack
Adams, A. (2018). Long-term study of the efficacy and safety of
OnabotulinumtoxinA for the prevention of chronic migraine:
COMPEL study. The journal of headache and pain, 19(1), 1-12.
Silberstein, S. (2016) The use of botulinum toxin in the management of
headache disorders. Semin Neurol 36: 92-98.
ora, S., Dodick, D., Diener, H., DeGryse, R., Turkel, C., Lipton, R. et al.
(2014) OnabotulinumtoxinA for chronic migraine: efficacy, safety,
and tolerability in patients who received all five treatment cycles in
the PREEMPT clinical program. Acta Neurol Scand 129: 61-70.
Cernuda-Morollon, E., Martinez-Camblor, P., Ramon, C., Larrosa, D.,
SerranoPertierra, E. and Pascual, J. (2014) CGRP and VIP levels as
predictors of efficacy of onabotulinumtoxin type A in Chronic
Migraine. Headache 54: 987-995.
Kollewe, K., Escher, C., Wulff, D., Fathi, D., Paracka, L., Mohammadi,
B. et 1. (2016) Long-term treatment of chronic migraine with
onabotulinumtoxinA: efficacy, quality of life and tolerability in a
real-life setting. J Neural Transm 123: 540_533AU.
Pradeep, R., Nemichandra, S. C., Harsha, S., & Radhika, K. (2020).
Migraine disability, quality of life, and its predictors. Annals of
neurosciences, 27(1), 18.
Zandieh, A., & Cutrer, F. M. (2022). OnabotulinumtoxinA in chronic
migraine: is the response dose dependent?. BMC neurology, 22(1),
-11.
https://www.healthcentral.com/article/botox-for-chronic-migraineknowledge-of-anatomy-is-critical.
Herd CP, Tomlinson CL, Rick C et al (2018) Botulinum toxins for the
prevention of migraine in adults. Cochrane Database Syst Rev
:CD011616
Aurora SK, Dodick DW, Turkel CC et al (2010) OnabotulinumtoxinA
for treatment of chronic migraine: results from the doubleblind,
randomized, placebo-controlled phase of the PREEMPT 1 trial.
Cephalalgia 30(7):793-803
Diener HC, Dodick DW, Aurora SK et al (2010) OnabotulinumtoxinA
for treatment of chronic migraine: results from the doubleblind,
randomized, placebo-controlled phase of the PREEMPT 2 trial. Cephalalgia 30(7):804-814.
Aljumah, M., Bunyan, R., Al Otaibi, H., Al Towaijri, G., Karim, A., Al Malik, Y., ... & Al-Jedai, A. (2020). Rising prevalence of multiple sclerosis in Saudi Arabia, a descriptive study. BMC neurology, 20,1-7.
Downloads
Published
Issue
Section
License
You are free to:
- Share — copy and redistribute the material in any medium or format for any purpose, even commercially.
- Adapt — remix, transform, and build upon the material for any purpose, even commercially.
- The licensor cannot revoke these freedoms as long as you follow the license terms.
Under the following terms:
- Attribution — You must give appropriate credit , provide a link to the license, and indicate if changes were made . You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
- No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
Notices:
You do not have to comply with the license for elements of the material in the public domain or where your use is permitted by an applicable exception or limitation .
No warranties are given. The license may not give you all of the permissions necessary for your intended use. For example, other rights such as publicity, privacy, or moral rights may limit how you use the material.
